Abstract
Background
Optimal treatment of Henoch-Schönlein purpura nephritis (HSN) remains unclear. We evaluated outcome of pediatric HSN patients treated initially with either methylprednisolone (MP) or cyclosporine A (CyA) in Finland between 1996 and 2011.
Methods
Outcome of 62 HSN patients was evaluated by screening urine and blood samples (n = 51) or by collecting clinical parameters from medical charts until last follow-up visit (n = 11). Sixty (97%) patients had nephrotic-range proteinuria and/or ISKDC grade ≥ III before initial treatment. Patients were initially treated with either MP pulses (n = 42) followed by oral prednisone or with CyA (n = 20). Fifty-nine (95%) patients received angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers.
Results
Mean follow-up time was 10.8 years (range 3.2–21.2 years). One patient developed end-stage renal disease and another had decreased renal function (eGFR < 60 mL/min/1.73m2), both initially treated with MP (3%). Six patients (5 MP, 1 CyA) had eGFR between 60 and 89 mL/min/1.73m2 (10%). Eighteen patients (13 MP, 5 CyA) had proteinuria and/or hematuria (29%) and four of them had proteinuria > 0.5 g/day at end of follow-up. Sixteen (38%) MP-treated and two (10%) CyA-treated patients needed additional immunosuppressive treatment (RR 3.81, 95% CI 1.16–14.3, p = 0.035). Late initiation of treatment was associated with an increased risk for persistent proteinuria.
Conclusions
Long-term outcome was relatively good in both treatment groups. However, since urinary abnormalities may persist or develop, long-term follow-up of HSN patients is mandatory. Early initiation of treatment had a favorable effect on proteinuria.
Similar content being viewed by others
References
Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR (2002) Incidence of henoch-schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 360:1197–1202
Saulsbury FT (2007) Clinical update: Henoch-schonlein purpura. Lancet 369:976–978
Narchi H (2005) Risk of long term renal impairment and duration of follow up recommended for henoch-schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 90:916–920
Koskimies O, Mir S, Rapola J, Vilska J (1981) Henoch-schonlein nephritis: long-term prognosis of unselected patients. Arch Dis Child 56:482–484
Stewart M, Savage JM, Bell B, McCord B (1988) Long term renal prognosis of Henoch-Schonlein purpura in an unselected childhood population. Eur J Pediatr 147:113–115
Goldstein AR, White RH, Akuse R, Chantler C (1992) Long-term follow-up of childhood Henoch-Schonlein nephritis. Lancet 339:280–282
Ronkainen J, Nuutinen M, Koskimies O (2002) The adult kidney 24 years after childhood Henoch-Schonlein purpura: a retrospective cohort study. Lancet 360:666–670
Hahn D, Hodson EM, Willis NS, Craig JC (2015) Interventions for preventing and treating kidney disease in Henoch-Schonlein purpura (HSP). Cochrane Database Syst Rev 8:CD005128
Niaudet P, Habib R (1998) Methylprednisolone pulse therapy in the treatment of severe forms of Schonlein-Henoch purpura nephritis. Pediatr Nephrol 12:238–243
Kawasaki Y, Suzuki J, Suzuki H (2004) Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: a clinical and histopathological study. Nephrol Dial Transplant 19:858–864
Ronkainen J, Autio-Harmainen H, Nuutinen M (2003) Cyclosporin A for the treatment of severe Henoch-Schonlein glomerulonephritis. Pediatr Nephrol 18:1138–1142
Shin JI, Park JM, Shin YH, Kim JH, Kim PK, Lee JS, Jeong HJ (2005) Cyclosporin A therapy for severe Henoch-Schonlein nephritis with nephrotic syndrome. Pediatr Nephrol 20:1093–1097
Park JM, Won SC, Shin JI, Yim H, Pai KS (2011) Cyclosporin A therapy for Henoch-Schonlein nephritis with nephrotic-range proteinuria. Pediatr Nephrol 26:411–417
Jauhola O, Ronkainen J, Autio-Harmainen H, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, Jahnukainen T, Rajantie J, Ormala T, Nuutinen M (2011) Cyclosporine A vs. methylprednisolone for Henoch-Schonlein nephritis: a randomized trial. Pediatr Nephrol 26:2159–2166
Ronkainen J, Koskimies O, Ala-Houhala M, Antikainen M, Merenmies J, Rajantie J, Ormala T, Turtinen J, Nuutinen M (2006) Early prednisone therapy in Henoch-Schonlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr 149:241–247
Kidney disease: Improving global outcomes (KDIGO) CKD work group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150
Whelton PK, Carey RM (2018) The 2017 American College of Cardiology/American Heart Association clinical practice guideline for high blood pressure in adults. JAMA Cardiol 3:352–353
Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EM, SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140:e20171904. https://doi.org/10.1542/peds.2017-1904
Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612
Vittinghoff E, McCulloch CE (2007) Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 165:710–718
Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, Jahnukainen T, Rajantie J, Ormala T, Turtinen J, Nuutinen M (2010) Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children. Arch Dis Child 95:877–882
Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, Jahnukainen T, Rajantie J, Ormala T, Nuutinen M (2012) Outcome of Henoch-Schonlein purpura 8 years after treatment with a placebo or prednisone at disease onset. Pediatr Nephrol 27:933–939
Wakaki H, Ishikura K, Hataya H, Hamasaki Y, Sakai T, Yata N, Kaneko T, Honda M (2011) Henoch-Schonlein purpura nephritis with nephrotic state in children: predictors of poor outcomes. Pediatr Nephrol 26:921–925
Scharer K, Krmar R, Querfeld U, Ruder H, Waldherr R, Schaefer F (1999) Clinical outcome of Schonlein-Henoch purpura nephritis in children. Pediatr Nephrol 13:816–823
Hennies I, Gimpel C, Gellermann J, Moller K, Mayer B, Dittrich K, Buscher AK, Hansen M, Aulbert W, Wuhl E, Nissel R, Schalk G, Weber LT, Pohl M, Wygoda S, Beetz R, Klaus G, Fehrenbach H, Konig S, Staude H, Beringer O, Bald M, Walden U, von Schnakenburg C, Bertram G, Wallot M, Haffner K, Wiech T, Hoyer PF, Pohl M, German Society of Pediatric Nephrology (2018) Presentation of pediatric Henoch-Schonlein purpura nephritis changes with age and renal histology depends on biopsy timing. Pediatr Nephrol 33:277–286
Shin JI, Park JM, Kim JH, Lee JS, Jeong HJ (2006) Factors affecting histological regression of crescentic Henoch-Schonlein nephritis in children. Pediatr Nephrol 21:54–59
Ninchoji T, Kaito H, Nozu K, Hashimura Y, Kanda K, Kamioka I, Shima Y, Hamahira K, Nakanishi K, Tanaka R, Yoshikawa N, Iijima K, Matsuo M (2011) Treatment strategies for Henoch-Schonlein purpura nephritis by histological and clinical severity. Pediatr Nephrol 26:563–569
Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linne T (2007) IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 18:1880–1888
Fretzayas A, Sionti I, Moustaki M, Papadimitriou A, Nicolaidou P (2008) Henoch-Schonlein purpura: a long-term prospective study in Greek children. J Clin Rheumatol 14:324–331
Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, Jahnukainen T, Rajantie J, Ormala T, Nuutinen M (2010) Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study. Arch Dis Child 95:871–876
Prais D, Amir J, Nussinovitch M (2007) Recurrent Henoch-Schonlein purpura in children. J Clin Rheumatol 13:25–28
Acknowledgements
We would like to thank Mrs. Anna Vuolteenaho for language editing.
Funding
This work was supported by a grant to M.K. from the Finnish Kidney Foundation, the Päivikki and Sakari Sohlberg Foundation, the Foundation for Paediatric Research, the Paulo Foundation, and the Alma and K.A. Snellman Foundation, Oulu, Finland.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Informed consent was obtained from all patients (and their guardians if necessary) who participated in the follow-up screening. The study was approved by the ethics committee of Helsinki University Hospital. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Supplementary Table S1
(PDF 201 kb)
Rights and permissions
About this article
Cite this article
Koskela, M., Jahnukainen, T., Endén, K. et al. Methylprednisolone or cyclosporine a in the treatment of Henoch-Schönlein nephritis: a nationwide study. Pediatr Nephrol 34, 1447–1456 (2019). https://doi.org/10.1007/s00467-019-04238-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-019-04238-2